Since seroflo rotacaps 50+500 mcg contains two active ingredients, fluticasone propionate and salmeterol, which represents two classes of medications, namely a synthetic corticosteroid and long-acting beta2-adrenergic receptor agonist. These have different clinical, physiologic and inflammatory effects on patients with asthma. These are the capsules of powdered formulation which are placed in a Rotahaler (an inhalation device). When you inhale, the rotahaler releases the combination medication for the rota cap. The medication directly reaches to the small airways if inhaled correctly, which increases the medication’s effectiveness. It relieves symptoms such as shortness of breath, coughing, wheezing, chest tightness, and coughing caused by asthma and chronic obstructive pulmonary disease (COPD). Rotacap medication is not recommended for use in patients less than twelve years of age. Your health care specialist may also prescribe seroflo Rotacaps as the maintenance treatment of asthma and is not suitable for patients with an acute or severe attack.